FeesSafety
Pluang+
Asset icon - trade crypto, stocks, and gold on Pluang

AstraZeneca plc (AZN) Stock Price Today

24H
1W
1M
3M
YTD
1Y
5Y

DNO ASA's offer for Capricorn Energy plc lapses, ending the acquisition attempt.

DNO ASA announced that its offer to acquire Capricorn Energy plc has lapsed as of November 9, 2026. This means the acquisition attempt will not proceed, impacting DNO's expansion plans in the oil and gas sector. Investors should monitor DNO's next st...

Market News
1 hour ago
Na
Neutral
DNO ASA's offer for Capricorn Energy plc lapses, ending the acquisition attempt.

Oculis to host R&D Day showcasing late-stage pipeline for dry eye and neuro-ophthalmology treatments

Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...

Market News
1 hour ago
Na
Bullish
news icon
Oculis to host R&D Day showcasing late-stage pipeline for dry eye and neuro-ophthalmology treatments

Fraudulent robocall losses in North America to drop 33% by 2031 due to advanced fraud prevention.

Juniper Research forecasts that losses from fraudulent robocalls in North America will decrease by 33%, from $18.4 billion in 2026 to $12.3 billion in 2031. This decline is attributed to telecom operators adopting advanced fraud prevention technologi...

Market News
1 hour ago
Juniper Research
Bullish
news icon
Fraudulent robocall losses in North America to drop 33% by 2031 due to advanced fraud prevention.

Novo Nordisk beats Q3 expectations, showing strong growth and a 34% upside potential.

Novo Nordisk's Q3 results exceeded expectations, driven by a 53% increase in pill sales and strong net patient growth, dispelling fears of oral product cannibalization. The company is also reducing capital expenditures and expanding free cash flow, s...

Company Fundamentals
5 hours ago
Seeking Alpha
Bullish
news icon
Novo Nordisk beats Q3 expectations, showing strong growth and a 34% upside potential.

VAALCO Energy advances to second exploration phase at Côte d'Ivoire Block CI-705 after successful initial work.

VAALCO Energy has completed the First Exploration Phase at Block CI-705 offshore Côte d'Ivoire and received government approval to proceed to the Second Exploration Phase. The block, where VAALCO holds a 70% interest, is located near existing oil fie...

Market News
6 hours ago
GlobeNewsWire
Bullish
news icon
VAALCO Energy advances to second exploration phase at Côte d'Ivoire Block CI-705 after successful initial work.

OTC Markets appoints Olivier Roguez as VP to boost market data growth in EMEA.

OTC Markets Group named Olivier Roguez Vice President, Market Data for the EMEA region to lead business development and market data growth. Roguez brings over 20 years of experience from Cboe Global Markets and other firms, aiming to expand OTC Marke...

Market News
6 hours ago
GlobeNewsWire
Bullish
news icon
OTC Markets appoints Olivier Roguez as VP to boost market data growth in EMEA.

Dapirolizumab pegol shows higher response rates and sustained remission in SLE patients versus placebo in Phase 3 trial.

Dapirolizumab pegol (DZP), an investigational biologic for systemic lupus erythematosus (SLE), demonstrated greater treatment response rates compared to placebo when combined with standard care in the Phase 3 PHOENYCS GO trial. Using a novel Treatmen...

Market News
7 hours ago
GlobeNewsWire
Bullish
news icon
Dapirolizumab pegol shows higher response rates and sustained remission in SLE patients versus placebo in Phase 3 trial.

ClearPoint Neuro posts strong Q3 with rising drug delivery revenue and promising future trials.

ClearPoint Neuro reported solid third-quarter results, driven by increased revenue from its drug delivery services and steady sales in neurosurgery navigation equipment. The company sees encouraging signs for future growth in disposables linked to ca...

Company Fundamentals
7 hours ago
Seeking Alpha
Bullish
news icon
ClearPoint Neuro posts strong Q3 with rising drug delivery revenue and promising future trials.

Investor uses technical analysis to target small-cap biotech stocks with promising Phase 2 progress.

David H. Lerner focuses on long-term biotech investments using technical analysis, emphasizing price action and volume rather than traditional fundamentals. He targets small-cap biotech companies advancing beyond Phase 2 trials, especially those deve...

9 hours ago
Seeking Alpha
Bullish
news icon
Investor uses technical analysis to target small-cap biotech stocks with promising Phase 2 progress.

Berkshire Hathaway holds more cash than stocks, signaling Buffett's cautious investment approach.

Berkshire Hathaway reported $377.4 billion in cash and Treasury bills, exceeding its $335.5 billion stock holdings as of Q3 2026. Warren Buffett maintains this large cash reserve as a safety floor against market downturns and to fund future acquisiti...

Market News
10 hours ago
24/7 Wall Street
Neutral
Berkshire Hathaway holds more cash than stocks, signaling Buffett's cautious investment approach.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

Key Stats

  • Market Cap
    $290.69B
  • Volume
    2,767,514
  • Sector
    Health
  • 52W High
    $209.48
  • 52W Low
    $155.62
  • Typical Hold Time
    126 Days
  • Enterprise Value
    $316.72B
  • Div Yield
    1.72%
  • Trading Activity
    -
$188.32
52W Low: $155.62
04 Aug 2026
52W High: $209.48
17 Feb 2026

Track AstraZeneca plc (AZN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, AstraZeneca plc has traded between a low of $155.62 and a high of $209.48, highlighting its annual price range. Buy and sell AstraZeneca plc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!